Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund ...
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...
TD Cowen analysts said in a note to investors that the third quarter was the third time in five years that Exact Sciences, ...
Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...
Investor's Business Daily on MSN6d
Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' FlopGuardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.
QRG Capital Management Inc. grew its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 13.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback